✉news HealthMedicine first seen 2 d ago, last 2 d ago, peak #37
MimiVax and Roswell Park Report SurVaxM Glioblastoma Trial Results
Original: MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the Phase 2b SURVIVE trial of SurVaxM, an investigational cancer vaccine, in patients with newly diagnosed glioblastoma. Glioblastoma is an aggressive brain cancer with few effective treatments, so outcomes from this trial are drawing attention from oncology researchers and patients awaiting new therapeutic options.
Why now: Trial results for a brain cancer vaccine matter to patients and clinicians given the lack of effective glioblastoma treatments.
MimiVaxRoswell Park Comprehensive Cancer CenterSurVaxMglioblastoma
Rank over time, top of the chart is #1. 3 snapshots from 2 d ago to 2 d ago.
Evidence
- MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma · Roswell Park Comprehensive Cancer Center
API: https://socialmediatrends-api.osmike.com/v1/trends/1380803